Overview
Galle Face Capital Partners is an investment company holding strategic positions in listed Sri Lankan equities across banking, hospitality, consumer, tobacco and healthcare. The key recent change is a sharp year-on-year reduction in June-quarter profit despite higher reported revenue, underlining that earnings are driven by portfolio outcomes rather than a stable operating sales base.
Price performance
At LKR 18.40 on 2 October 2026, the share had fallen 16.9% over three months, versus a 6.3% decline for the ASPI. The 20 March 1:4 split means these returns are restated onto today's share basis, separating the economic price movement from the mechanical change in shares.
The share sits near the bottom of its 52-week range. Its three-year record contains five falls of 15% or more, with the latest drawdown yet to recover, so past price weakness has often persisted for months rather than reversing immediately.
Liquidity is limited: median daily turnover was LKR 378,514 over the past 60 sessions, and a LKR 1 million order is more than everything that trades on a typical day, at 264.2% of it. Building or exiting a position of that size therefore represents a large part of normal daily trading.
Valuation
The P/E of 2.5 times means the market price is LKR 2.50 for every LKR 1 of trailing profit, and it sits at the 0th percentile among sector peers with usable P/E data. It is also the cheapest day in the company's record since January 2019, although the low multiple rests on investment income that has varied sharply between quarters.
The P/B of 0.75 times means a buyer pays 75 cents for each rupee of reported net assets. It is cheaper than 74% of days since January 2019, while trailing ROE of 21.9% helps explain why the portfolio has generated meaningful returns on its equity base despite the discount to book value.
News and sentiment
Direct company coverage was normal, with six material articles over 90 days: two positive and four neutral. The material development was a rights issue reported on 2 October, proposed on a 1:1 basis at LKR 16 per share; its ex-date has not yet been set.
The CSE also reported a trading halt on 31 August pending disclosure, lifted on 1 September. A scrip dividend disclosure was reported in September, but the latest recorded cash dividend's ex-date has already passed, so a buyer today does not receive it.
Financials
For the June 2026 quarter, revenue grew 76.2% year-on-year but net profit fell 72.2% to LKR 83.5 million. For an investment company, reported revenue does not capture all portfolio-related income, so the profit outcome is more informative than the sales line alone.
No gross margin is supplied. Operating margin was 118.1% versus 709.2% a year earlier, while net margin was 112.0% versus 710.1%; profit can exceed the revenue line because of investment and other income. Against comparable June quarters, operating margin ranked fifth and net margin fourth among eight observations, making the latest result middling within its own June history rather than an extreme.
Below-the-line items reduced June operating profit by LKR 4.5 million. The March 2026 1:4 split increased ordinary shares from 29.6 million to 118.3 million without changing stated capital, so per-share comparisons across the event need that mechanical adjustment; the absolute June profit decline remains the more relevant measure of portfolio performance.
Risks
The principal risk is portfolio-income volatility: June net profit was 72.2% below the comparable quarter despite reported revenue growth, showing how quickly investment gains and income can change. The announced 1:1 rights issue at LKR 16 introduces a further uncertainty around the eventual capital base and the deployment of new funds.
Balance-sheet leverage was modest at the March 2026 year-end, with liabilities equal to 0.09 times equity. That limits financing pressure, but it does not remove the risk that the value and income of listed investee holdings fluctuate with Sri Lankan equity-market and economic conditions.
Outlook
As at 2 October 2026, the next material update is the September 2026 interim filing, expected between 6 and 14 November. It will replace the June-quarter evidence and show whether the lower portfolio profit was followed by a stronger or weaker quarter.
The announced rights issue has no fixed ex-date; based on the exchange record available on 2 October, its ex-date is expected between 27 October 2026 and 20 January 2027. The filing confirms the proposed terms but does not yet establish the final timing or how the additional capital will be deployed.